2022
A randomized controlled pilot trial of anakinra for hemodialysis inflammation
Dember L, Hung A, Mehrotra R, Hsu J, Raj D, Charytan D, Mc Causland F, Regunathan-Shenk R, Landis J, Kimmel P, Kliger A, Himmelfarb J, Ikizler T, Consortium H. A randomized controlled pilot trial of anakinra for hemodialysis inflammation. Kidney International 2022, 102: 1178-1187. PMID: 35863559, PMCID: PMC9588554, DOI: 10.1016/j.kint.2022.06.022.Peer-Reviewed Original ResearchConceptsPatient-reported outcomesPlacebo groupAdverse eventsMedian decreaseHemodialysis patientsIL-6IL-1 receptor antagonistRate of adverse eventsEffect of anakinraPlacebo-controlled trialBaseline to weekAnti-cytokine therapyIL-1 inhibitionAssociated with morbidityAnakinra groupReceptor antagonistBetween-group differencesEfficacy outcomesAnakinraMaintenance hemodialysisRandomized controlled pilot trialChronic inflammationEvaluate safetyPlaceboIL-1
2021
Transforming the Care of Patients with Diabetic Kidney Disease
Brosius FC, Cherney D, Gee PO, Harris RC, Kliger A, Tuttle KR, Quaggin SE. Transforming the Care of Patients with Diabetic Kidney Disease. Clinical Journal Of The American Society Of Nephrology 2021, 16: 1590-1600. PMID: 34103350, PMCID: PMC8499007, DOI: 10.2215/cjn.18641120.Commentaries, Editorials and LettersConceptsRenin-angiotensin system inhibitorsDiabetic kidney diseaseIrbesartan Diabetic Nephropathy TrialCare of patientsKidney diseaseSystem inhibitorsNew therapiesAngiotensin II Antagonist Losartan (RENAAL) trialAngiotensin II type 1 receptor blockerDiabetic kidney disease progressionType 1 receptor blockerCardiovascular protective therapiesReduction of EndpointsKidney disease progressionKidney protective effectsRenin-angiotensin systemDiabetic Nephropathy TrialRisk of deathHigh residual riskHealth care providersPowerful new therapiesNephropathy TrialReceptor blockersDevastating complicationAntihypertensive agents
2010
In-Center Hemodialysis Six Times per Week versus Three Times per Week
Chertow G, Levin N, Beck G, Depner T, Eggers P, Gassman J, Gorodetskaya I, Greene T, James S, Larive B, Lindsay R, Mehta R, Miller B, Ornt D, Rajagopalan S, Rastogi A, Rocco M, Schiller B, Sergeyeva O, Schulman G, Ting G, Unruh M, Star R, Kliger A. In-Center Hemodialysis Six Times per Week versus Three Times per Week. New England Journal Of Medicine 2010, 363: 2287-2300. PMID: 21091062, PMCID: PMC3042140, DOI: 10.1056/nejmoa1001593.Peer-Reviewed Original ResearchConceptsLeft ventricular massPhysical health composite scoresFrequent hemodialysisComposite outcomeVascular accessVentricular massSelf-reported depressionConventional hemodialysisCardiac magnetic resonance imagingConventional hemodialysis groupErythropoiesis-stimulating agentsRate of hospitalizationSerum albumin concentrationComposite scoreSelf-reported physical healthCognitive performanceMagnetic resonance imagingMaintenance hemodialysisSecondary outcomesBlood pressureLaboratory markersCenter hemodialysisClinical trialsMineral metabolismHealth Survey
1996
Continuous Peritoneal Dialysis-Associated Peritonitis of Nosocomial Origin
Troidle L, Kliger A, Goldie S, Gorban-Brennan N, Brown E, Fikrig M, Finkelstein F. Continuous Peritoneal Dialysis-Associated Peritonitis of Nosocomial Origin. Advances In Peritoneal Dialysis 1996, 16: 505-510. PMID: 8914180, DOI: 10.1177/089686089601600513.Peer-Reviewed Case Reports and Technical NotesMeSH KeywordsAge FactorsAgedAnti-Bacterial AgentsCardiovascular DiseasesComorbidityConnecticutCross InfectionDiabetes MellitusDrug Resistance, MicrobialEnterococcusFemaleGastrointestinal DiseasesGram-Negative Bacterial InfectionsGram-Positive Bacterial InfectionsHIV SeropositivityHospitalizationHumansIncidenceLength of StayMaleMiddle AgedPatient AdmissionPeripheral Vascular DiseasesPeritoneal Dialysis, Continuous AmbulatoryPeritonitisRetrospective StudiesRisk FactorsSerum AlbuminStaphylococcal InfectionsTreatment OutcomeVancomycinConceptsAcute care hospitalsNosocomial peritonitisCPD patientsSpectrum of organismsCPD therapyInvasive proceduresHuman immunodeficiency virus seropositivityPeritoneal Dialysis-Associated PeritonitisAntecedent antibiotic usePeripheral vascular diseaseContinuous peritoneal dialysisMean serum albuminStandard antibiotic therapyPossible risk factorsAntecedent antibioticsHospital stayComorbid diseasesNineteen patientsRenal functionStrains of EnterococcusAntibiotic therapyRetrospective reviewNP patientsPeritoneal dialysisVirus seropositivityFungal peritonitis in a large chronic peritoneal dialysis population: a report of 55 episodes
Goldie S, Kiernan-Troidle L, Torres C, Gorban-Brennan N, Dunne D, Kliger A, Finkelstein F. Fungal peritonitis in a large chronic peritoneal dialysis population: a report of 55 episodes. American Journal Of Kidney Diseases 1996, 28: 86-91. PMID: 8712227, DOI: 10.1016/s0272-6386(96)90135-3.Peer-Reviewed Original ResearchConceptsDiagnosis of FPEpisodes of FPPrior antibiotic useFungal peritonitisTenckhoff catheterRisk factorsCPD therapyPeritonitis rateAntibiotic useChronic peritoneal dialysis therapyEnd-stage renal diseaseEarly catheter removalEpisodes of peritonitisPeritoneal dialysis populationPeritoneal dialysis therapyCatheter replacementTemporary hemodialysisCatheter removalDialysis populationCPD patientsRenal diseaseSerious complicationsDialysis therapyHigh morbidityTherapy 1
1995
Enalapril treatment of posttransplant erythrocytosis: efficacy independent of circulating erythropoietin levels
Perazella M, McPhedran P, Kliger A, Lorber M, Levy E, Bia M. Enalapril treatment of posttransplant erythrocytosis: efficacy independent of circulating erythropoietin levels. American Journal Of Kidney Diseases 1995, 26: 495-500. PMID: 7645558, DOI: 10.1016/0272-6386(95)90496-4.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedEnalaprilErythropoietinFemaleHematocritHumansKidney TransplantationMaleMiddle AgedPolycythemiaTreatment OutcomeConceptsRed blood cell massBlood cell massErythropoietin levelsEnalapril therapyPosttransplant erythrocytosisHemoglobin concentrationMU/mLElevated red blood cell massMean reticulocyte countRed blood cell destructionRenal transplant patientsMean pretreatment valuePlasma volume contractionMean levelsMean hemoglobin concentrationBlood cell destructionRed blood cell productionMechanism of actionEnalapril treatmentTransplant patientsMean hematocritPretreatment valuesBlood cell productionReticulocyte countEnzyme inhibitors
1994
Abdominal Abscesses Complicating Peritonitis in Continuous Ambulatory Peritoneal Dialysis Patients
Boroujerdi-Rad H, Juergensen P, Mansourian V, Kliger A, Finkelstein F. Abdominal Abscesses Complicating Peritonitis in Continuous Ambulatory Peritoneal Dialysis Patients. American Journal Of Kidney Diseases 1994, 23: 717-721. PMID: 8172214, DOI: 10.1016/s0272-6386(12)70282-2.Peer-Reviewed Original ResearchMeSH KeywordsAbscessAdultFemaleHumansMaleMiddle AgedPeritoneal Dialysis, Continuous AmbulatoryPeritonitisTreatment OutcomeConceptsAbdominal abscessIntraperitoneal abscessContinuous ambulatory peritoneal dialysis-associated peritonitisContinuous ambulatory peritoneal dialysis (CAPD) therapyContinuous ambulatory peritoneal dialysis (CAPD) patientsPeritoneal dialysis-associated peritonitisEnd-stage renal diseaseAmbulatory peritoneal dialysis patientsDialysis-associated peritonitisPeritoneal dialysis unitCommon presenting symptomEpisodes of peritonitisPeritoneal dialysis patientsAbdominal wall abscessesPeritoneal dialysis therapyComputed tomography scanningIndium scanningAbdominal painPeritonitis episodesPresenting symptomDialysis patientsPrompt diagnosisRenal diseaseUncommon complicationAbscess cavity